Which has better valuation & earnings, ABBV or INCY?

AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $61.16B 7.43 $4.23B $3.54 72.65 Incyte $5.82B 4.23 $1.29B $7.85 15.47

Is ABBV or INCY more profitable?

Incyte has a net margin of 27.71% compared to AbbVie's net margin of 9.80%. Incyte's return on equity of 29.93% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 9.80% -422.07% 14.34% Incyte 27.71% 29.93% 22.88%

Does the media prefer ABBV or INCY?

In the previous week, AbbVie had 70 more articles in the media than Incyte. MarketBeat recorded 89 mentions for AbbVie and 19 mentions for Incyte. AbbVie's average media sentiment score of 1.30 beat Incyte's score of 0.98 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 69 Very Positive mention(s) 8 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 9 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to REGN or INCY?

In the previous week, Regeneron Pharmaceuticals had 30 more articles in the media than Incyte. MarketBeat recorded 49 mentions for Regeneron Pharmaceuticals and 19 mentions for Incyte. Incyte's average media sentiment score of 0.98 beat Regeneron Pharmaceuticals' score of 0.70 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 19 Very Positive mention(s) 4 Positive mention(s) 22 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 9 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ARGX or INCY?

argenex has higher earnings, but lower revenue than Incyte. Incyte is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 14.50 $1.29B $26.04 37.80 Incyte $5.82B 4.23 $1.29B $7.85 15.47

Is ARGX or INCY more profitable?

argenex has a net margin of 32.19% compared to Incyte's net margin of 27.71%. argenex's return on equity of 43.59% beat Incyte's return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Incyte 27.71% 29.93% 22.88%

Does the media prefer ARGX or INCY?

In the previous week, Incyte had 13 more articles in the media than argenex. MarketBeat recorded 19 mentions for Incyte and 6 mentions for argenex. Incyte's average media sentiment score of 0.98 beat argenex's score of 0.72 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 9 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, MRNA or INCY?

Incyte has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $2.21B 26.01 -$2.82B -$7.99 N/A Incyte $5.82B 4.23 $1.29B $7.85 15.47

Is MRNA or INCY more profitable?

Incyte has a net margin of 27.71% compared to Moderna's net margin of -141.43%. Incyte's return on equity of 29.93% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Incyte 27.71% 29.93% 22.88%

Does the media refer more to MRNA or INCY?

In the previous week, Moderna had 7 more articles in the media than Incyte. MarketBeat recorded 26 mentions for Moderna and 19 mentions for Incyte. Incyte's average media sentiment score of 0.98 beat Moderna's score of 0.55 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 8 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Incyte 9 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, NTRA or INCY?

Incyte has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.56 -$208.16M -$1.36 N/A Incyte $5.82B 4.23 $1.29B $7.85 15.47

Is NTRA or INCY more profitable?

Incyte has a net margin of 27.71% compared to Natera's net margin of -7.11%. Incyte's return on equity of 29.93% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% Incyte 27.71% 29.93% 22.88%

Does the media refer more to NTRA or INCY?

In the previous week, Natera and Natera both had 19 articles in the media. Natera's average media sentiment score of 1.21 beat Incyte's score of 0.98 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 9 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Incyte (INCY) Competitors

$121.47 -1.81 (-1.47%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$119.95 -1.52 (-1.25%)

As of 09/11/2026 07:30 PM Eastern

Compare

INCY vs. ABBV, REGN, ARGX, MRNA, and NTRA

Should you buy Incyte stock or one of its competitors? Incyte's main competitors and comparable companies include AbbVie (ABBV), Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), and Natera (NTRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Incyte compare to AbbVie?

AbbVie (NYSE:ABBV) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

AbbVie presently has a consensus price target of $276.64, suggesting a potential upside of 7.57%. Incyte has a consensus price target of $124.05, suggesting a potential upside of 2.12%. Given AbbVie's stronger consensus rating and higher possible upside, equities analysts clearly believe AbbVie is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52

Incyte has a net margin of 27.71% compared to AbbVie's net margin of 9.80%. Incyte's return on equity of 29.93% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Incyte	27.71%	29.93%	22.88%

In the previous week, AbbVie had 70 more articles in the media than Incyte. MarketBeat recorded 89 mentions for AbbVie and 19 mentions for Incyte. AbbVie's average media sentiment score of 1.30 beat Incyte's score of 0.98 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	69 Very Positive mention(s)	8 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbbVie has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Incyte has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.43	$4.23B	$3.54	72.65
Incyte	$5.82B	4.23	$1.29B	$7.85	15.47

70.2% of AbbVie shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

AbbVie beats Incyte on 10 of the 17 factors compared between the two stocks.

How does Incyte compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Incyte's net margin of 27.71%. Incyte's return on equity of 29.93% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Incyte	27.71%	29.93%	22.88%

Regeneron Pharmaceuticals has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$15.53B	5.18	$4.50B	$40.46	19.32
Incyte	$5.82B	4.23	$1.29B	$7.85	15.47

In the previous week, Regeneron Pharmaceuticals had 30 more articles in the media than Incyte. MarketBeat recorded 49 mentions for Regeneron Pharmaceuticals and 19 mentions for Incyte. Incyte's average media sentiment score of 0.98 beat Regeneron Pharmaceuticals' score of 0.70 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	19 Very Positive mention(s)	4 Positive mention(s)	22 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Incyte has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Regeneron Pharmaceuticals presently has a consensus price target of $802.18, suggesting a potential upside of 2.65%. Incyte has a consensus price target of $124.05, suggesting a potential upside of 2.12%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52

Summary

Regeneron Pharmaceuticals beats Incyte on 10 of the 17 factors compared between the two stocks.

How does Incyte compare to argenex?

argenex (NASDAQ:ARGX) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

argenex has a net margin of 32.19% compared to Incyte's net margin of 27.71%. argenex's return on equity of 43.59% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Incyte	27.71%	29.93%	22.88%

argenex presently has a consensus price target of $1,158.61, indicating a potential upside of 17.70%. Incyte has a consensus price target of $124.05, indicating a potential upside of 2.12%. Given argenex's stronger consensus rating and higher possible upside, research analysts clearly believe argenex is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52

In the previous week, Incyte had 13 more articles in the media than argenex. MarketBeat recorded 19 mentions for Incyte and 6 mentions for argenex. Incyte's average media sentiment score of 0.98 beat argenex's score of 0.72 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has higher earnings, but lower revenue than Incyte. Incyte is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	14.50	$1.29B	$26.04	37.80
Incyte	$5.82B	4.23	$1.29B	$7.85	15.47

argenex has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Incyte has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

60.3% of argenex shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

argenex beats Incyte on 11 of the 17 factors compared between the two stocks.

How does Incyte compare to Moderna?

Moderna (NASDAQ:MRNA) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Moderna has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, Incyte has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Incyte has a net margin of 27.71% compared to Moderna's net margin of -141.43%. Incyte's return on equity of 29.93% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Incyte	27.71%	29.93%	22.88%

Moderna presently has a consensus price target of $76.72, indicating a potential downside of 46.71%. Incyte has a consensus price target of $124.05, indicating a potential upside of 2.12%. Given Incyte's stronger consensus rating and higher probable upside, analysts clearly believe Incyte is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52

In the previous week, Moderna had 7 more articles in the media than Incyte. MarketBeat recorded 26 mentions for Moderna and 19 mentions for Incyte. Incyte's average media sentiment score of 0.98 beat Moderna's score of 0.55 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	9 Very Positive mention(s)	8 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.21B	26.01	-$2.82B	-$7.99	N/A
Incyte	$5.82B	4.23	$1.29B	$7.85	15.47

75.3% of Moderna shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Incyte beats Moderna on 14 of the 17 factors compared between the two stocks.

How does Incyte compare to Natera?

Natera (NASDAQ:NTRA) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Incyte has a net margin of 27.71% compared to Natera's net margin of -7.11%. Incyte's return on equity of 29.93% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Incyte	27.71%	29.93%	22.88%

99.9% of Natera shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Natera and Natera both had 19 articles in the media. Natera's average media sentiment score of 1.21 beat Incyte's score of 0.98 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera presently has a consensus target price of $330.83, suggesting a potential upside of 0.58%. Incyte has a consensus target price of $124.05, suggesting a potential upside of 2.12%. Given Incyte's higher possible upside, analysts clearly believe Incyte is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52

Incyte has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.56	-$208.16M	-$1.36	N/A
Incyte	$5.82B	4.23	$1.29B	$7.85	15.47

Natera has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Incyte has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Summary

Incyte beats Natera on 9 of the 16 factors compared between the two stocks.

Get Incyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCY vs. The Competition

Export

Metric	Incyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.99B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	15.47	14.25	275.24	25.29
Price / Sales	4.23	1,473.06	655.99	98.94
Price / Cash	19.95	106.68	77.04	51.44
Price / Book	4.62	15.12	10.33	6.20
Net Income	$1.29B	-$22.86M	$3.50B	$358.50M
7 Day Performance	-4.17%	-4.34%	-3.32%	-2.35%
1 Month Performance	0.58%	-0.02%	-0.41%	-2.77%
1 Year Performance	46.17%	40.64%	19.21%	7.63%

Incyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCY Incyte	3.4986 of 5 stars	$121.47 -1.5%	$124.05 +2.1%	+41.0%	$24.99B	$5.82B	15.47	2,844	News Coverage Analyst Forecast
ABBV AbbVie	4.1052 of 5 stars	$256.95 +0.6%	$275.95 +7.4%	+16.8%	$451.38B	$61.16B	72.58	57,000	Trending News Dividend Announcement Analyst Forecast
REGN Regeneron Pharmaceuticals	3.82 of 5 stars	$799.08 +0.6%	$800.36 +0.2%	+37.5%	$81.77B	$14.34B	19.75	15,410	Trending News Analyst Forecast
ARGX argenex	4.5464 of 5 stars	$1,031.66 +0.8%	$1,158.61 +12.3%	+28.9%	$64.01B	$4.25B	39.62	1,863
MRNA Moderna	2.1302 of 5 stars	$140.34 +1.7%	$80.53 -42.6%	+467.0%	$55.09B	$1.94B	N/A	4,700	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCY) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incyte (INCY) Competitors